ROCA Therapeutics
medicinal chemistry

First-in-Class Medicines against Uveal Melanoma and its Neovascular complications

« First-in-Class Drugs against ocular diseases driven by hyper-vascularization and immuno-suppressive inflammation »

A united team creating an innovative therapy to give a new vision to patients.

hexagon title

About us

Roca Therapeutics is a VC financed biotechnology start-up dedicated to the development of First In Class Small molecules.

Located in Nice (France), Roca Therapeutics is a spin-off from Nice University and SATT Sud Est, incubated by the PACA-Est incubator.
Roca has an internationally recognized team of Directors and Advisors with a strong track record of Translational Research and Drug Development in Oncology, Ophtalmology and Immunology.

Directors

with recognized track record and well established collaborations

Founding Team - hexagons background
Dr Roberto De Ponti

Dr Roberto De Ponti

Director Board Member

Managing Director and General

Partner of 3B FUTUR Health Fund

30+ years of experience as senior director in pharmaceutical companies

Dr Gilles Pagès

Dr Gilles Pagès

Director Board Member

DR1 INSERM

IRCAN - UCA, Monaco

30+ years experience in oncology R&D and translational research

Dr Maeva Dufies

Dr Maeva Dufies

CEO - Director Board Member

CR2 CNRS

IRCAN - UCA, Nice, France

10+ years of experience in Oncology R&D
and translational research

Dr Rachid Benhida

Dr Rachid Benhida

Director Board Member

DR1 CNRS

ICN - UCA, Nice, France

30+ years of experience in drug R&D and biotech

Dr Cyril Ronco

Dr Cyril Ronco

Director Board Member

Maître de Conférences HDR

ICN - UCA, Nice, France

15+ years of experience in Medicinal Chemistry and drug R&D

Mr Zaki Sellam

Mr Zaki Sellam

Chairman of the Board of Directors

MSc - MBA, Basel, Switzerland

20+ years in drug development in oncology-immunology, creation and financing of biotech start-ups

Advisory Board

Dr Lauris Gastaud

Dr Lauris Gastaud

Oncologist 

Centre Antoine Lacassagne

Nice, France

Specialist in uveal melanoma

honeycomb background
honeycomb background

Dr Sergio Roman Roman

Research Director

Institut Curie

Paris, France

Specialist in uveal melanoma

Dr Sergio Roman Roman
honeycomb background
programs table
honeycomb background
Dr Olivier Loget

Dr Olivier Loget

CEO and Chairman

CapEval Pharma

Archamps, France

Specialist in toxicology, clinical ophthalmology and biotech

Pr Stéphanie Baillif

Head of department of Ophthalmology

CHU de Nice, France

Specialist in eye diseases including uveal melanoma

Pr Stéphanie Baillif

Roca is building a dedicated Advisory Board allowing an approach against UM from biology to cancer and ocular complications

Dr Arnaud Jacquel

Dr Arnaud Jacquel

Researcher

Centre Méditerranéen de Médecine Moléculaire, Nice, France

Specialist in onco-hematology 

and innate immunity

Dr Patrick Auberger

Research Director

Centre Méditerranéen de Médecine Moléculaire, Nice, France

Specialist in onco-hematology and innate immunity

Dr Patrick Auberger
Dr Andréas Bikfalvi

Dr Andréas Bikfalvi

Research Director

Inserm - ACML

Bordeaux, France

Specialist in physiological and pathological angiogenesis

honeycomb background
honeycomb background
title hexagon

Science & Pipeline

Science

The historical investigators i.e Dr Gilles Pagès, Dr Maeva Dufies, Dr Cyril Ronco and Dr Rachid Benhida have combined their expertise for the last 10 years in Medicinal Chemistry and Oncology/Immunology Translational research to build a promising portfolio of patent protected First In Class molecules able to address exacerbated/resistant mechanisms of angiogenesis, chronic immunosuppressive inflammation in the context of neoplastic and neovascular disorders. 


Roca Therapeutics approach is to be a holistic disease driven company addressing not only Uveal melanoma from a cancer treatment perspective but also addressing its severely impairing neovascular glaucoma resulting from proton-therapy.


Aware of the promising potential around its portfolio, Roca is also evaluating other neoplastic and neovascular disorders as secondary indications.

Pipeline

programs table

Programs

Lead optimisation

IND enabling studies

Clinical

Goal

red arrow

Metastasic Uveal Melanoma

RCT001

Treatment of primary and metastatic form of Uveal Melanoma

Treatment and prevention of the neovascular comp-lications after proton therapy such as glau-coma and retinopathy

blue arrow

Neovascular Complications

RCT002

honeycomb background
hexagons background
title hexagon

News & Events

Awards / Investments

pipeline arrow

2020

2022

awards
investments
course line
course line
course line
course line
course line
incubateur PACA-Est

Incubation 

3B

Secured Lead investor 3B FUTURE Health Fund

SATT Sud-Est

Global exclusive licence

white hexagons
BPI France

FrenchTech Emergence

Eurobiomed

Competitivity pole

white hexagon
white hexagon
SATT Sud-Est

Investment

Cancéropole PACA

funding

Canceropole PACA
i-Lab

Innovation Award

i-Lab

Innovation Award

white hexagon
ROCA Therapeutics

Incorporation 

PIA3

PIA3 

Award

Roca Therapeutics is surrounded by several local and national strategic partners: IRCAN, ICN, Centre Antoine Lacassagne, CNRS, University Côte d’Azur, SATT Sud-Est, Canceropole PACA, Incubator Paca-Est, Eurobiomed, …

Roca Therapeutics has been rewarded by recognized prizes: i-Lab, bpifrance BFTE, PIA3, Amgen Prize, …

Roca Therapeutics is founded by a lead corporate VC and has been backed by several non-dilutive financings.

Partners

Deeptech
3B future health fund
CHU Nice
Centre Antoine Lacassagne
Incubateur PACA-Est
BPI France
SATT Sud-Est
ICN
UCA
i-Lab
cnrs
IRCAN
inserm
Métropole Nice CA
hexagon title

Contact

www.roca-therapeutics.org

ROCA Therapeutics
thank you

FOR VISITING US